CURRENT
ISSUE
1705

The FDA has approved an oral extended-release formulation of gepirone (Exxua – Fabre-Kramer), a selective 5-HT1A receptor agonist, for treatment of major depressive disorder (MDD) in adults. Gepirone was originally developed decades ago for treatment of anxiety and depression, but it was not approved by the FDA for such use. Gepirone is structurally related to buspirone, which is FDA-approved for treatment of anxiety.1

STANDARD TREATMENT — Selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs),...  Continue reading

Coming Soon
Drugs for Postmenopausal Osteoporosis
Iloprost (Aurlumyn) for Frostbite
Cefepime/Enmetazobactam (Exblifep) for Complicated Urinary Tract Infections
Pilocarpine 0.4% Ophthalmic Solution (Qlosi) for Presbyopia